NCT02175693View on ClinicalTrials.gov

Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia

CompletedOBSERVATIONAL
Enrollment

1,647

Participants

Timeline

Start Date

April 2, 2013

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Cervical Dystonia
Trial Locations (2)

Unknown

Osaka

Tokyo

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT02175693 - Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia | Biotech Hunter | Biotech Hunter